| Dr Joel Scott Bray, | |
|
601 3rd St N, Soperton, GA 30457-1160 | |
| (912) 529-4774 | |
| (912) 529-4409 |
| Full Name | Dr Joel Scott Bray |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 601 3rd St N, Soperton, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457467219 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 052278 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pineland Mhmrsa | 6002898616 | 8 |
News Archive
As Bahrain implements reforms following protests that started last year, a significant number of patients – from all political and religious backgrounds - continue to avoid seeking medical care in public hospitals due to perceived discrimination, harassment, and ill treatment, the international medical humanitarian organisation Médecins Sans Frontières said today.
OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.
The economic uncertainty and healthcare issues affecting millions of Americans have hit the nation's cardiologists as well, according to a new survey: they are seeing more "baby boomer" patients than ever as Americans get older and demand more care. But they are being reimbursed less for those services by Medicare and insurance firms, in what one cardiologist calls "a revenue roller coaster of uncertainty."
Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.
› Verified 2 days ago
| Entity Name | Pineland Mhmrsa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588735252 PECOS PAC ID: 6002898616 Enrollment ID: O20040607000175 |
News Archive
As Bahrain implements reforms following protests that started last year, a significant number of patients – from all political and religious backgrounds - continue to avoid seeking medical care in public hospitals due to perceived discrimination, harassment, and ill treatment, the international medical humanitarian organisation Médecins Sans Frontières said today.
OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.
The economic uncertainty and healthcare issues affecting millions of Americans have hit the nation's cardiologists as well, according to a new survey: they are seeing more "baby boomer" patients than ever as Americans get older and demand more care. But they are being reimbursed less for those services by Medicare and insurance firms, in what one cardiologist calls "a revenue roller coaster of uncertainty."
Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel Scott Bray, 549 Prince Ave, Swainsboro, GA 30401-5721 Ph: () - | Dr Joel Scott Bray, 601 3rd St N, Soperton, GA 30457-1160 Ph: (912) 529-4774 |
News Archive
As Bahrain implements reforms following protests that started last year, a significant number of patients – from all political and religious backgrounds - continue to avoid seeking medical care in public hospitals due to perceived discrimination, harassment, and ill treatment, the international medical humanitarian organisation Médecins Sans Frontières said today.
OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.
The economic uncertainty and healthcare issues affecting millions of Americans have hit the nation's cardiologists as well, according to a new survey: they are seeing more "baby boomer" patients than ever as Americans get older and demand more care. But they are being reimbursed less for those services by Medicare and insurance firms, in what one cardiologist calls "a revenue roller coaster of uncertainty."
Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).
A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.
› Verified 2 days ago